Curative Biotechnology, Inc.

Equities

CUBT

US23128N1081

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 23:00:00 14/05/2024 BST			5-day change	1st Jan Change
0.02 ^USD	-7.24%		-20.00%	-6.10%

05-06	Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	CI

Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.

October 31, 2022 at 04:00 am

Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,553,398
PriceRange: $5.15
Discount Per Security: $0.3605

Latest news about Curative Biotechnology, Inc.

Curative Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05-06	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	11-25	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.	07/09/23	CI
Curative Biotechnology, Inc. Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions	07/06/23	CI
Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study	05/01/23	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	16/11/22	CI
Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.	07/11/22	CI
Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.	31/10/22	CI
Curative Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	01/09/22	CI
Curative Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/06/22	CI
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors	16/06/22	CI
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors	12/05/22	CI
Curative Biotechnology, Inc. has filed an IPO.	15/04/22	CI
Curative Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt	14/04/22	CI
Curative Biotechnology Announces Cooperative Research and Development Agreement with the National Eye Institute	21/03/22	CI
Curative Biotechnology, Inc. announced that it has received $1 million in funding	20/03/22	CI
Curative Biotechnology, Inc. announced that it expects to receive $1 million in funding	03/03/22	CI
Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular Degeneration	24/11/21	CI
Curative Biotechnology, Inc. Auditor Raises 'Going Concern' Doubt	23/11/21	CI
Curative Biotechnology, Inc. Appoints Dr. Catherine Sohn as Special Advisor to Board and CEO	12/10/21	CI
Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine	07/10/21	CI
Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board	02/09/21	CI
Curative Biotechnology, Inc. has Changed its Ticker to CUBT from CTYX	29/04/21	CI
Curative Biotechnology, Inc. Announces Additions to Scientific and Clinical Advisory Board	29/04/21	CI
Connectyx Technologies Holdings Group, Inc. Announces Management Changes	11/02/21	CI

Chart Curative Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CURATIVE BIOTECHNOLOGY, INC.	-6.10%	18.07M
MODERNA, INC.	+30.76%	49.46B
IQVIA HOLDINGS INC.	+1.22%	42.58B
LONZA GROUP AG	+49.22%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+12.89%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-23.76%	18.64B
BIO-TECHNE CORPORATION	+7.36%	13.16B
MEDPACE HOLDINGS, INC.	+31.44%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.07%	12.1B

Other Biotechnology & Medical Research